EMERALD-1
The first trial to show that adding immunotherapy and an anti-VEGF drug to TACE delays progression in intermediate-stage liver cancer.
PFS 15.0 vs 8.2 months for TACE + durvalumab + bevacizumab vs TACE alone (HR 0.77); OS trended (HR 0.80) but was not statistically significant at follow-up. Published in The Lancet 2025.
- Median 15 vs 8.2 months with TACE + durvalumab + bevacizumab compared with TACE + placebo; about 6.8 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 23 percent lower chance of the event at any given time (hazard ratio 0.77, likely range 0.61 to 0.98).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- The treated group had about 20 percent lower chance of the event at any given time (hazard ratio 0.8).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- The likely range for the hazard ratio crosses 1, so the difference could be due to chance.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Embolisation-eligible unresectable HCC: TACE + durvalumab ± bevacizumab vs TACE + placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
616 participants enrolled.
Numbers not yet public.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | TACE + durvalumab + bevacizumab | — | 15 months | 0.77 (0.61–0.98) | — | — |
| TACE + placebo | — | 8.2 months | ||||
| Overall survival | TACE + durvalumab + bevacizumab | — | — | 0.8 (0.57–1.11) | — | — |
| TACE + placebo | — | — |
Pages like this
not linked directly; found by shared links- TrialEMERALD-3
Shares TACE + immunotherapy/anti-VEGF, Transarterial chemoembolisation (TACE), Durvalumab, Hepatocellular carcinoma.
- TrialLEAP-012
Shares TACE + immunotherapy/anti-VEGF, Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- CompanyBoston Scientific
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TermTACE (transarterial chemoembolisation)
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TermPortal vein tumour thrombus (macrovascular invasion)
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TermTARE / SIRT (radioembolisation with yttrium-90)
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TermDownstaging and conversion therapy
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TrialHIMALAYA
Shares Durvalumab, Hepatocellular carcinoma.